105 related articles for article (PubMed ID: 27319350)
1. Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis.
Villadangos JA
Immunol Rev; 2016 Jul; 272(1):169-82. PubMed ID: 27319350
[TBL] [Abstract][Full Text] [Related]
2. Target Density, Not Affinity or Avidity of Antigen Recognition, Determines Adoptive T Cell Therapy Outcomes in a Mouse Lymphoma Model.
Segal G; Prato S; Zehn D; Mintern JD; Villadangos JA
J Immunol; 2016 May; 196(9):3935-42. PubMed ID: 27036915
[TBL] [Abstract][Full Text] [Related]
3. Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold.
Prato S; Zhan Y; Mintern JD; Villadangos JA
J Immunol; 2013 Oct; 191(7):3534-44. PubMed ID: 24018271
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T cells reactive to an immunodominant leukemia-associated antigen can be specifically primed and expanded by combining a specific priming step with nonspecific large-scale expansion.
Ghosh A; Wolenski M; Klein C; Welte K; Blazar BR; Sauer MG
J Immunother; 2008; 31(2):121-31. PubMed ID: 18481382
[TBL] [Abstract][Full Text] [Related]
5. Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".
García-Guerrero E; Sánchez-Abarca LI; Domingo E; Ramos TL; Bejarano-García JA; Gonzalez-Campos JA; Caballero-Velázquez T; Pérez-Simón JA
Front Immunol; 2018; 9():1971. PubMed ID: 30233577
[TBL] [Abstract][Full Text] [Related]
6. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
7. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
[TBL] [Abstract][Full Text] [Related]
8. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
[TBL] [Abstract][Full Text] [Related]
9. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
10. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
11. Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells.
Bao H; Wu D
Curr Stem Cell Res Ther; 2017; 12(3):188-196. PubMed ID: 28025936
[TBL] [Abstract][Full Text] [Related]
12. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
13. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
14. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
[TBL] [Abstract][Full Text] [Related]
15. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
Okada H; Tsugawa T; Sato H; Kuwashima N; Gambotto A; Okada K; Dusak JE; Fellows-Mayle WK; Papworth GD; Watkins SC; Chambers WH; Potter DM; Storkus WJ; Pollack IF
Cancer Res; 2004 Aug; 64(16):5830-8. PubMed ID: 15313927
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment.
Bathe OF; Dalyot-Herman N; Malek TR
BMC Cancer; 2003 Jul; 3():21. PubMed ID: 12882650
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.
Sandri S; Bobisse S; Moxley K; Lamolinara A; De Sanctis F; Boschi F; Sbarbati A; Fracasso G; Ferrarini G; Hendriks RW; Cavallini C; Scupoli MT; Sartoris S; Iezzi M; Nishimura MI; Bronte V; Ugel S
Cancer Res; 2016 May; 76(9):2540-51. PubMed ID: 27197263
[TBL] [Abstract][Full Text] [Related]
18. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
19. In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire.
Ho WY; Nguyen HN; Wolfl M; Kuball J; Greenberg PD
J Immunol Methods; 2006 Mar; 310(1-2):40-52. PubMed ID: 16469329
[TBL] [Abstract][Full Text] [Related]
20. [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
Liu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):244-8. PubMed ID: 15157343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]